3.1.3.48	((1E)-2-nitroprop-1-en-1-yl)benzene	50% inhibition at 0.023 mM in absence of 2-mercaptoethanol, at 0.515 mM in presence of 1 mM 2-mercaptoethanol	129281	
3.1.3.48	((2-bromo-4-((((2E)-3-phenylprop-2-en-1-yl)sulfanyl)methyl)phenyl)carbonyl)phosphonate	50% inhibition at 810 nM for wild-type, at 1290 nM for mutant S295F	129715	
3.1.3.48	((2-bromo-4-(((4-chlorobenzyl)thio)methyl)phenyl)(difluoro)methyl)phosphonate	50% inhibition at 285 nM for wild-type, at 1644 nM for mutant S295F	129709	
3.1.3.48	((2-phenyl-2-(phenylcarbonyl)propane-1,3-diyl)bis(benzene-4,1-diyl(difluoromethanediyl)))bis(phosphonate)	50% inhibition at 82 nM for wild-type, at 399 nM for mutant S295F	129711	
3.1.3.48	((4-((((3'-(acetylsulfamoyl)biphenyl-4-yl)methyl)sulfanyl)methyl)-2-bromophenyl)(difluoro)methyl)phosphonate	50% inhibition at 2.2 nM for wild-type, at 11 nM for mutant S295F	129710	
3.1.3.48	((4-((4E)-2-(1,3-benzothiazol-2-yl)-2-(1H-benzotriazol-1-yl)-5-phenylpent-4-en-1-yl)phenyl)(difluoro)methyl)phosphonate	50% inhibition at 47 nM for wild-type, at 260 nM for mutant S295F	129712	
3.1.3.48	((4-((4E)-2-(1,3-benzothiazol-2-yl)-2-(1H-benzotriazol-1-yl)-5-phenylpent-4-en-1-yl)phenyl)(fluoro)methyl)phosphonate	50% inhibition at 570 nM for wild-type, at 830 nM for mutant S295F	129713	
3.1.3.48	((4-((4E)-2-(1H-benzotriazol-1-yl)-2,5-diphenylpent-4-en-1-yl)phenyl)(difluoro)methyl)phosphonic acid	50% inhibition at 109 nM for isoform PTP-1B, at 95 nM for isoform TCPTP	129699	
3.1.3.48	((E)-2-nitrovinyl)benzene	i.e. trans-beta-nitrostyrene, slow-binding inhibitor, acting as a pY mimetic and binding to the enzyme active site to form an initial noncovalent E*I complex, followed by nucleophilic attack on the nitrostyrene nitro group by C215 of enzyme to form a reversible, covalent adduct. 50% inhibition at 0.0025 mM in absence of 2-mercaptoethanol, at 0.4 mM in presence of 1 mM 2-mercaptoethanol	129277	
3.1.3.48	(1-benzyl-3-methyl-2,3-dihydro-1H-imidazol-2-yl)(chloro)gold	i.e. [(BzMeIm)AuICl]	158944